Business Wire

CA-ALTIUM-LLC

4.6.2020 09:02:08 CEST | Business Wire | Press release

Share
Altium Launches Initiatives to Help Electronics Industry Get “Back to Work”

From home offices to virtual workplaces, the working environment has changed. For the Printed Circuit Board (PCB) design industry, Altium has helped make the transition seamless, empowering collaboration across every aspect of the design process. With Altium 365, the world’s only cloud-based platform for PCB design and realization, many of Altium’s customers were able to stay in motion even during the most challenging times.

As the world gets back to business, Altium is making it easy for PCB designers to continue to work from anywhere and connect with anyone.

“The workplace is more distributed than ever before, and at the same time our customers are dealing with unprecedented financial challenges,” says Ted Pawela, Altium’s COO. “We want to help the industry get back on track by making it easier than ever before to get the tools they need for PCB design, and work collaboratively in distributed work environments.”

Coming Together Without Impacting Workflow

Altium’s newest cloud-based platform, Altium 365, creates a connected experience throughout the PCB development and manufacturing process, making it easy to share PCB designs and collaborate in real-time with anyone - in any time zone, at any company, from anywhere - as the design evolves.

The platform has proven to be essential for PCB designers worldwide, including the teams working on the Open Source Ventilator Project , a global coalition of engineers, designers and medical practitioners. With Altium 365, PCB designers were able to co-design with mechanical engineers, in real-time via an easy online platform to finalize the designs.

As Douglas Karnazes, Founder and CEO of Velocity Research and member of the Open Source Ventilator Project elaborates, ‘When you have 3,000 people working on a project, labor and software is unlimited; the only limitation is time. We needed close collaboration with this many people, working from all over the world, all working from home, and Altium 365 helped pull everyone together.”

Salt Lake City’s Cirris Systems adopted Altium 365 just before workspaces shifted from physical to virtual. The need for remote work options would have been overwhelming for Cirris System’s one-man IT department, but with Altium 365, the company was able to transition to remote work without the need for new servers, VPNs or any downtime.

As Orlan Thatcher, Board Layout Specialist at Cirrius Systems, elaborates, “Our electrical engineers and myself have been using Altium 365 every day from our homes to do everything from sharing designs to preserving tight revision and process controls, that our bigger aerospace and aviation clients now expect.”

Altium Designer users do not have to change the way they work today to take advantage of Altium 365. The PCB design team at SkyShips , a Tier One automotive manufacturer of Infotainment systems, is using Altium 365 to align the global engineering team during the entire development process.

“We use the Altium 365 workspaces as a way to keep all our components, designs and projects all in one place, so that everyone is working from the same source of information. We are able to design faster with teams at different locations, “ stated Chris Brawn, Senior Design Engineer at SkyShips.

Making PCB Design Tools Accessible for Everyone

Altium has rolled out several initiatives to keep the electronics industry moving forward, including aggressive pricing for Altium Designer perpetual licenses with Altium 365 subscriptions. Altium is also allowing customers to pay in installments over a 12-month period, for those customers whose businesses are strapped for cash.

The newly launched Altium Designer Refer-a-Friend Program is another exciting opportunity for users to share their passion for Altium’s tools with their friends and colleagues and be rewarded. This newly launched program allows users to refer colleagues to purchase Altium Designer via a unique referral link accessible for current Altium Designer customers. When used to purchase a new license of Altium Designer, participants earn cash rewards.

ABOUT ALTIUM

Altium LLC (ASX:ALU ), a global software company headquartered in San Diego, Calif., is accelerating the pace of innovation through electronics. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.

The growing demand for smart and connected products is driving advancements in electronics technology. Design trends are demonstrating the need for minimizing power, reducing package size and energy consumption, and prioritizing high-speed design. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers, from idea to board. Users are at the center of Altium’s R&D and business operations. With its unique Business-to-User approach, Altium is focused on developing software that is easy to use and implement, with solutions that enable innovation and deliver industry-leading user productivity. Products include Altium Designer® , Altium Concord Pro™, Altium 365® , Altium NEXUS® , CircuitMaker® , CircuitStudio® , Octopart® , and TASKING® . To learn more about Altium, visit www.altium.com .

Social Media:

https://www.facebook.com/AltiumOfficial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye